Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Li G., Cappuccini F., Marchevsky NG., Aley PK., Aley R., Anslow R., Bibi S., Cathie K., Clutterbuck E., Faust SN., Feng S., Heath PT., Kerridge S., Lelliott A., Mujadidi Y., Ng KF., Rhead S., Roberts H., Robinson H., Roderick MR., Singh N., Smith D., Snape MD., Song R., Tang K., Yao A., Liu X., Lambe T., Pollard AJ., Aboagye J., Ambihapathy W., Baker JF., Beales ER., Boon A., Brampton R., Branch NM., Cooper R., Cornish EL., Cuevas-Asturias S., Danos Z., Davies S., de Luna George L., Drury R., Flaxman A., Fowler J., Galiza E., Godfrey L., Haskell L., Hillson K., Hultin CL., Koleva S., Lees E., Mabbett R., Muller J., Munro APS., Oliver AL., Owens DR., Pearce JP., Rajan M., Ratcliffe H., Rowbotham I., Salter S., Sanders H., Sapuan SS., Sharpe H., Sheehan E., Sutton N., Thaygaraja G., Thomson-Hill S., Ulaszewska M., Woods D., Bristol Clinical Research Nurse Team None.

DOI

10.1016/s0140-6736(22)00770-x

Type

Journal article

Journal

The Lancet

Publisher

Elsevier BV

Publication Date

06/2022

Volume

399

Pages

2212 - 2225

Permalink Original publication